Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Treatment of M1a/M1b prostate cancer with or without radical prostatectomy at diagnosis




The aim of the study was to evaluate survival and perioperative outcomes of metastatic prostate cancer (mPCa) patients treated with surgery or androgen deprivation treatment (ADT) only.


We retrospectively selected 47 metastatic PCa patients treated at a single center (Mayo Clinic, Rochester, MN) by two urologists (RJK and EK) between 2007 and 2014. Overall, 31 (66%) underwent radical prostatectomy (RP) with or without adjuvant therapies and 16 (34%) underwent ADT only. Surgical patients were treated by a single surgeon (RJK). Complications and functional outcomes were recorded for surgery group. Cancer-specific mortality (CSM) was analyzed by Kaplan–Meier estimation. Univariable Cox regression analyses were used to test the risk factors associated with CSM in mPCa patients treated with RP.


Median age at diagnosis was 61 years. During median follow-up 38.8 months, 12 deaths were recorded. At 5 years, the overall CSM-free survival rate of the whole cohort was 57.9%. When patients were stratified according to the treatment, CSM-free survival rate at 5 years was 62% and 46% for patients who underwent surgery and ADT, respectively (P=0.3). Median length of stay was 3 days, with a 30 days readmission rate of 9.7%. The 30-day all complication rate was 29% (n=9). Specifically, we recorded: 2 lymphoceles (6.5%), 2 wound infection (6.5%), 2 ileus (6.5%), 2 hematoma (6.5%) and 1 anastomosis leak (3.2%). Within 90 days after surgery, 2 (6.5%) and 5 (16.1%) patients needed 1–2 supportive and 3 or more pads, respectively. However, continence was achieved by all treated patients during the follow-up period.


We demonstrated the feasibility of local surgical treatment of primary tumor in mPCa patients. However, in the short term, no survival benefits have been observed for patients treated with surgery when compared with patients treated with ADT only. Further prospective studies are warranted to explore the treatment of M1a/M1b prostate cancer patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others


  1. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D’Amico AV et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw 2014; 12: 686–718.

    Article  CAS  Google Scholar 

  2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65: 467–479.

    Article  CAS  Google Scholar 

  3. De Angelis G, Rittenhouse HG, Mikolajczyk SD, Blair Shamel L, Semjonow A . Twenty years of PSA: from prostate antigen to tumor marker. Rev Urol 2007; 9: 113–123.

    PubMed  PubMed Central  Google Scholar 

  4. Wu JN, Fish KM, Evans CP, Devere White RW, Dall’Era MA . No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 2014; 120: 818–823.

    Article  CAS  Google Scholar 

  5. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655–1659.

    Article  CAS  Google Scholar 

  6. Aben KKH, Heskamp S, Janssen-Heijnen ML, Koldewijn EL, Van Herpen CM, Kiemeney LA et al. Better survival in patients with metastasised kidney cancer after nephrectomy: a population-based study in the Netherlands. Eur J Cancer 2011; 47: 2023–2032.

    Article  CAS  Google Scholar 

  7. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ . Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248–1259.

    Article  Google Scholar 

  8. Temple LKF, Hsieh L, Wong WD, Saltz L, Schrag D . Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol 2004; 22: 3475–3484.

    Article  Google Scholar 

  9. Shao Y-HJ, Kim S, Moore DF, Shih W, Lin Y, Stein M et al. Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis. Eur Urol 2014; 65: 693–700.

    Article  Google Scholar 

  10. Fossati N, Trinh Q-D, Sammon J, Sood A, Larcher A, Sun M et al. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol 2015; 67: 3–6.

    Article  Google Scholar 

  11. Gratzke C, Engel J, Stief CG . Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol 2014; 66: 602–603.

    Article  Google Scholar 

  12. Culp SH, Schellhammer PF, Williams MB . Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014; 65: 1058–1066.

    Article  Google Scholar 

  13. Satkunasivam R, Kim AE, Desai M, Nguyen MM, Quinn DI, Ballas L et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a seer-medicare analysis. J Urol 2015; 194: 378–385.

    Article  Google Scholar 

  14. Antwi S, Everson TM . Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: a population-based, propensity score analysis. Cancer Epidemiol 2014; 38: 435–441.

    Article  Google Scholar 

  15. Heidenreich A, Pfister D, Porres D . Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol 2015; 193: 832–838.

    Article  Google Scholar 

  16. Sooriakumaran P, Karnes J, Stief C, Copsey B, Montorsi F, Hammerer P et al. A Multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol 2015; 69: 788–794.

    Article  Google Scholar 

  17. Dindo D, Demartines N, Clavien P-A . Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205–213.

    Article  Google Scholar 

  18. Psaila B, Lyden D . The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009; 9: 285–293.

    Article  CAS  Google Scholar 

  19. Langley RR, Fidler IJ . The seed and soil hypothesis revisited—the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011; 128: 2527–2535.

    Article  CAS  Google Scholar 

  20. Fidler IJ . The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 2003; 3: 453–458.

    Article  CAS  Google Scholar 

  21. Gandaglia G, Fossati N, Dell’Oglio P, Moschini M, Cucchiara V, Suardi N et al. Rationale for local treatment in the management of metastatic prostate cancer. Curr Opin Support Palliat Care 2016; 10: 266–272.

    Article  Google Scholar 

  22. Moschini M, Soria F, Briganti A, Shariat SF . The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients. Prostate Cancer Prostatic Dis 2016; doi:10.1038/pcan.2016.52.

  23. Löppenberg B, Dalela D, Karabon P, Sood A, Sammon JD, Meyer CP et al. The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis. Eur Urol 2016; doi:10.1016/j.eururo.2016.04.031.

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to R J Karnes.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moschini, M., Morlacco, A., Kwon, E. et al. Treatment of M1a/M1b prostate cancer with or without radical prostatectomy at diagnosis. Prostate Cancer Prostatic Dis 20, 117–121 (2017).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links